PGXL Labs Adopts AutoGenomics' Infiniti System for Warfarin, CYP450 Testing
April 05, 2011
PGXL Labs Adopts AutoGenomics' Infiniti System for Warfarin, CYP450 Testing
PGXL, a Louisville, Ky.-based pharmacogenomics services provider, plans to introduce other AutoGenomics assays, such as its KRAS-BRAF test, in the future.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- AutoGenomics Lowers Proceeds Expected from IPO
January 23, 2013 / GenomeWeb Daily News - PGXL, AutoGenomics Partner on Personalized Medicine
April 1, 2011 / GenomeWeb Daily News - AutoGenomics Launches Familial Mediterranean Fever Panel, Plans FDA Submission
January 25, 2011 / BioArray News - NMTC's 'Italian Soap Opera' Leaves Luminex Crowing 'Nice Win' While GenMark Cuts Guidance
June 18, 2013 / BioArray News - Arrays Increasingly Adopted for Stillbirth Studies, though Questions about Cost, Counseling Remain
June 18, 2013 / BioArray News